Company: HURA
Filing Date: 2025-02-07
Form Type: S-4
Source: 0001193125-25-022803
Chunk: 771

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-02-07
Form: S-4
Chunk 771
---
 an entity to recognize assets and liabilities arising from a lease for both financing and operating leases, along with additional qualitative and quantitative disclosures. ASU 2016-02is effective for the fiscal years beginning after December 15, 2021, with early adoption permitted. The Company has adopted this standard as of January 1, 2022, which did not result in any changes to opening stockholders’ equity balances. Income Taxes– Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Grant Income –In April 2021, the Company received approval from the Department of Health and Human Services for a $ 400,000 grant. The grant was to conduct research for a low-cost topical immunotherapy formulation suitable for treating cervical cancer in low and middle-income countries and low resource settings in the U.S. The Company received a final grant payment in May 2023 totaling approximately $ 42,000 . Research and Development Expenses– Research and development consists of expenses incurred in connection with the discovery and development of product candidates. The Company expenses research and development costs as incurred. Acquired In-ProcessResearch and Development –Acquired in-processresearch and development expenses consist of existing research and development projects at the time of the acquisition. Projects that qualify as IPR&D assets represent those that have not yet reached technological feasibility and had no alternative future use, which resulted in a write-offof these IPR&D assets to acquired in-processresearch and development expenses in our consolidated statements of operations. Concentration of Credit Risk– The Company maintains cash balances in banks. These balances are insured by the Federal Deposit Insurance Corporation up to $ 250,000. As of December 31, 2023, the uninsured portion of cash held by the Company was approximately $ 3,220,000. Fair Value of Financial Instruments– ASC 820, Fair Value Measurement, establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company’s own assumptions (unobservable inputs). Observable inputs are inputs that market F-5 3

TUHURA BIOSCIENCES, INC. AND SUBSIDIARY Notes to the consolidated financial statements For the years ended December 31, 2023, and 2022

participants would use in pricing the asset or liability based on market data obtained